Cartesian Therapeutics

Historical price data

Cartesian Therapeutics is a clinical-stage biotech leader focused on developing mRNA cell therapies for autoimmune diseases. The company's proprietary platform is designed to engineer a patient's own cells with mRNA to produce therapeutic proteins directly at the site of disease, potentially offering a more targeted and transient treatment approach. Its lead candidate, Descartes-08, is in Phase 2 development for myasthenia gravis, representing a novel application of cell therapy beyond oncology. The company is publicly traded and is advancing a pipeline aimed at bringing 21st-century treatments to patients with autoimmune disorders.

A proprietary mRNA platform for engineering patient-derived cells (e.g., T cells) to transiently produce therapeutic proteins, aiming to treat autoimmune diseases with a targeted and potentially safer approach than permanent gene modification.

12 drugs in pipeline, 1 in Phase 3

Total raised: $175M

Cartesian competes with large pharma companies marketing autoimmune biologics and with a growing number of biotechs developing cell therapies for autoimmunity, such as Kyverna and Cabaletta Bio. Its key differentiation is the use of mRNA for transient engineering, which it posits offers a superior safety profile.